Skip to main content

Table 1 Patient characteristics of the SEER-Oncotype cohort. P values were calculated by t-test and chi-squared test for continuous and categorical characteristics, respectively

From: Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use

  Users (n = 89,255) Non-users (n = 286,095) P value
Mean age (SD) 57.8 (10.0) 59.5 (11.5) <1e−314
Stage (%)    <1e−314
 I 58,512 (65.6) 132,415 (46.3)  
 II 29,494 (33.0) 97,347 (34.0)  
 III 1104 (1.2) 40,265 (14.1)  
 IV 145 (0.2) 16,068 (5.6)  
Grade (%)    <1e−314
 I 70,648 (26.1) 25,215 (28.9)  
 II 126,526 (46.8) 47,690 (54.7)  
 III 73,256 (27.1) 14,338 (16.4)  
Lymph node (%)    <1e−314
 Negative 76,401 (85.6) 174,024 (60.8)  
 Positive 12,848 (14.4) 109,956 (38.4)  
 Unknown 6 (0.0) 2115 (0.8)  
HER2 (%) a    <1e−314
 Negative 62,115 (95.3) 112,187 (78.2)  
 Positive 1199 (1.8) 24,469 (17.1)  
 Unknown 1889 (2.9) 6850 (4.7)  
Race (%)    3.E−71
 White 73,722 (82.6) 230,090 (80.4)  
 Black 7129 (8.0) 69,307 (10.0)  
 Asian 6837 (7.7) 22,592 (7.9)  
 Other 1293 (1.4) 3962 (1.4)  
 Unknown 274 (0.3) 851 (0.3)  
Chemotherapy (%)    <1e−314
 No/unknown 67,853 (77.7) 159,334 (55.7)  
 Yes 19,948 (22.3) 126,761 (44.3)  
Radiation therapy (%)    7.E−313
 No/unknown 34,763 (38.9) 132,040 (46.2)  
 Yes 54,492 (61.1) 154,055 (53.8)  
  1. a Since only samples after 2009 contained breast cancer subtype information, the displayed percentages include patients from 2010 to 2015 only